25
Participants
Start Date
November 1, 2021
Primary Completion Date
December 31, 2024
Study Completion Date
December 31, 2024
Venetoclax combined with azacitidine regimen
Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-21); azacitidine 75 mg/m2 subcutaneously once daily on days 1-7 .
The First Affliated Hospital of Soochow University, Suzhou
Jining Medical University
OTHER
The Second People's Hospital of Huai'an
OTHER
The First Affiliated Hospital of Bengbu Medical University
OTHER
Affiliated Hospital of Nantong University
OTHER
Suzhou Hospital of Traditional Chinese Medicine
OTHER
The First Affiliated Hospital of Anhui Medical University
OTHER
Southern Medical University, China
OTHER
Nanyang Central Hospital of Henan Province
UNKNOWN
Canglang Hospital of Suzhou
UNKNOWN
The First Affiliated Hospital of Soochow University
OTHER